Suppressed expression of Cbl‐b by <i>NF‐κB</i> mediates icotinib resistance in EGFR‐mutant non‐small‐cell lung cancer
Tieqiong Zhang(First Hospital of China Medical University), Xuejun Hu(Zoucheng People's Hospital), Yibo Fan(The University of Texas MD Anderson Cancer Center), Huan Zhao(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaofang Che(First Hospital of China Medical University), Jian Kang(Seoul National University), Ye Zhang(University of Electronic Science and Technology of China), Jinyao Wang(Nankai University), Kezuo Hou(First Hospital of China Medical University), Xiujuan Qu(First Hospital of China Medical University), Yunpeng Liu(Shenyang Institute of Automation), Chunlei Zheng(First Hospital of China Medical University)
Cited by 10
Related Papers
Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study
|The Lancet|2018|1.8k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Prevalence, risk factors, and management of asthma in China: a national cross-sectional study
|The Lancet|2019|773
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657